Department of Clinical Oncology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
Expert Rev Anticancer Ther. 2014 Aug;14(8):865-8. doi: 10.1586/14737140.2014.928595. Epub 2014 Jun 13.
Esophageal Squamous Cell Carcinoma (ESCC) is a heterogeneous tumor with enormous genetic and epigenetic changes. RNA editing is an epigenetic mechanism that serves as an additional layer of 'RNA mutations' in parallel to DNA mutations. The most frequent type of RNA editing, A-to-I (adenosine-to-inosine) editing catalyzed by Adenosine DeAminase that act on RNA (ADARs), modulates RNA transcripts with profound impact on cellular functions. RNA editing dysregulation has been found to be associated with cancers. Our recent study demonstrated that among all the three RNA editing enzymes, only ADAR1 was overexpressed in primary ESCCs compared with matched non-tumor specimens. In this review, we will discuss current views on the involvement of abnormal A-to-I editing in cancer development, more specifically on the ADAR1-mediated editing in ESCC. Although much is not yet learned about the role of ADAR1 in ESCC, ADAR1 may present an attractive option as a new biomarker for ESCC and as a new molecular therapeutic target.
食管鳞状细胞癌（ESCC）是一种具有巨大遗传和表观遗传变化的异质性肿瘤。RNA 编辑是一种表观遗传机制，作为 DNA 突变的平行“RNA 突变”的附加层。最常见的 RNA 编辑类型是由作用于 RNA 的腺苷脱氨酶（ADARs）催化的 A-to-I（腺苷到肌苷）编辑，它调节 RNA 转录本，对细胞功能有深远影响。RNA 编辑失调已被发现与癌症有关。我们最近的研究表明，在所有三种 RNA 编辑酶中，与匹配的非肿瘤标本相比，只有 ADAR1 在原发性 ESCC 中过表达。在这篇综述中，我们将讨论异常 A-to-I 编辑在癌症发展中的作用的最新观点，更具体地说，是 ADAR1 介导的 ESCC 编辑。尽管人们对 ADAR1 在 ESCC 中的作用了解甚少，但 ADAR1 可能作为 ESCC 的新生物标志物和新的分子治疗靶点具有吸引力。
